Cargando…

Investigations of the Copper Peptide Hepcidin-25 by LC-MS/MS and NMR (+)

Hepcidin-25 was identified as the main iron regulator in the human body, and it by binds to the sole iron-exporter ferroportin. Studies showed that the N-terminus of hepcidin is responsible for this interaction, the same N-terminus that encompasses a small copper(II)-binding site known as the ATCUN...

Descripción completa

Detalles Bibliográficos
Autores principales: Abbas, Ioana M., Vranic, Marija, Hoffmann, Holger, El-Khatib, Ahmed H., Montes-Bayón, María, Möller, Heiko M., Weller, Michael G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6121404/
https://www.ncbi.nlm.nih.gov/pubmed/30072660
http://dx.doi.org/10.3390/ijms19082271
_version_ 1783352459796676608
author Abbas, Ioana M.
Vranic, Marija
Hoffmann, Holger
El-Khatib, Ahmed H.
Montes-Bayón, María
Möller, Heiko M.
Weller, Michael G.
author_facet Abbas, Ioana M.
Vranic, Marija
Hoffmann, Holger
El-Khatib, Ahmed H.
Montes-Bayón, María
Möller, Heiko M.
Weller, Michael G.
author_sort Abbas, Ioana M.
collection PubMed
description Hepcidin-25 was identified as the main iron regulator in the human body, and it by binds to the sole iron-exporter ferroportin. Studies showed that the N-terminus of hepcidin is responsible for this interaction, the same N-terminus that encompasses a small copper(II)-binding site known as the ATCUN (amino-terminal Cu(II)- and Ni(II)-binding) motif. Interestingly, this copper-binding property is largely ignored in most papers dealing with hepcidin-25. In this context, detailed investigations of the complex formed between hepcidin-25 and copper could reveal insight into its biological role. The present work focuses on metal-bound hepcidin-25 that can be considered the biologically active form. The first part is devoted to the reversed-phase chromatographic separation of copper-bound and copper-free hepcidin-25 achieved by applying basic mobile phases containing 0.1% ammonia. Further, mass spectrometry (tandem mass spectrometry (MS/MS), high-resolution mass spectrometry (HRMS)) and nuclear magnetic resonance (NMR) spectroscopy were employed to characterize the copper-peptide. Lastly, a three-dimensional (3D) model of hepcidin-25 with bound copper(II) is presented. The identification of metal complexes and potential isoforms and isomers, from which the latter usually are left undetected by mass spectrometry, led to the conclusion that complementary analytical methods are needed to characterize a peptide calibrant or reference material comprehensively. Quantitative nuclear magnetic resonance (qNMR), inductively-coupled plasma mass spectrometry (ICP-MS), ion-mobility spectrometry (IMS) and chiral amino acid analysis (AAA) should be considered among others.
format Online
Article
Text
id pubmed-6121404
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-61214042018-09-07 Investigations of the Copper Peptide Hepcidin-25 by LC-MS/MS and NMR (+) Abbas, Ioana M. Vranic, Marija Hoffmann, Holger El-Khatib, Ahmed H. Montes-Bayón, María Möller, Heiko M. Weller, Michael G. Int J Mol Sci Article Hepcidin-25 was identified as the main iron regulator in the human body, and it by binds to the sole iron-exporter ferroportin. Studies showed that the N-terminus of hepcidin is responsible for this interaction, the same N-terminus that encompasses a small copper(II)-binding site known as the ATCUN (amino-terminal Cu(II)- and Ni(II)-binding) motif. Interestingly, this copper-binding property is largely ignored in most papers dealing with hepcidin-25. In this context, detailed investigations of the complex formed between hepcidin-25 and copper could reveal insight into its biological role. The present work focuses on metal-bound hepcidin-25 that can be considered the biologically active form. The first part is devoted to the reversed-phase chromatographic separation of copper-bound and copper-free hepcidin-25 achieved by applying basic mobile phases containing 0.1% ammonia. Further, mass spectrometry (tandem mass spectrometry (MS/MS), high-resolution mass spectrometry (HRMS)) and nuclear magnetic resonance (NMR) spectroscopy were employed to characterize the copper-peptide. Lastly, a three-dimensional (3D) model of hepcidin-25 with bound copper(II) is presented. The identification of metal complexes and potential isoforms and isomers, from which the latter usually are left undetected by mass spectrometry, led to the conclusion that complementary analytical methods are needed to characterize a peptide calibrant or reference material comprehensively. Quantitative nuclear magnetic resonance (qNMR), inductively-coupled plasma mass spectrometry (ICP-MS), ion-mobility spectrometry (IMS) and chiral amino acid analysis (AAA) should be considered among others. MDPI 2018-08-02 /pmc/articles/PMC6121404/ /pubmed/30072660 http://dx.doi.org/10.3390/ijms19082271 Text en © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Abbas, Ioana M.
Vranic, Marija
Hoffmann, Holger
El-Khatib, Ahmed H.
Montes-Bayón, María
Möller, Heiko M.
Weller, Michael G.
Investigations of the Copper Peptide Hepcidin-25 by LC-MS/MS and NMR (+)
title Investigations of the Copper Peptide Hepcidin-25 by LC-MS/MS and NMR (+)
title_full Investigations of the Copper Peptide Hepcidin-25 by LC-MS/MS and NMR (+)
title_fullStr Investigations of the Copper Peptide Hepcidin-25 by LC-MS/MS and NMR (+)
title_full_unstemmed Investigations of the Copper Peptide Hepcidin-25 by LC-MS/MS and NMR (+)
title_short Investigations of the Copper Peptide Hepcidin-25 by LC-MS/MS and NMR (+)
title_sort investigations of the copper peptide hepcidin-25 by lc-ms/ms and nmr (+)
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6121404/
https://www.ncbi.nlm.nih.gov/pubmed/30072660
http://dx.doi.org/10.3390/ijms19082271
work_keys_str_mv AT abbasioanam investigationsofthecopperpeptidehepcidin25bylcmsmsandnmr
AT vranicmarija investigationsofthecopperpeptidehepcidin25bylcmsmsandnmr
AT hoffmannholger investigationsofthecopperpeptidehepcidin25bylcmsmsandnmr
AT elkhatibahmedh investigationsofthecopperpeptidehepcidin25bylcmsmsandnmr
AT montesbayonmaria investigationsofthecopperpeptidehepcidin25bylcmsmsandnmr
AT mollerheikom investigationsofthecopperpeptidehepcidin25bylcmsmsandnmr
AT wellermichaelg investigationsofthecopperpeptidehepcidin25bylcmsmsandnmr